Download PDF
Pharmacopsychiatry 2013; 46(06): 201-208
DOI: 10.1055/s-0033-1347177
Review
© Georg Thieme Verlag KG Stuttgart · New York

Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review Part II: Antipsychotics

A. La Torre
1   U.O. di Psichiatria, Ospedale di Rovereto, Rovereto (Tn), Italy
,
A. Conca
2   Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy
,
D. Duffy
2   Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy
,
G. Giupponi
2   Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy
,
M. Pompili
3   Department of Psychiatry, Sant’Andrea Hospital, “La Sapienza” University of Rome, Rome, Italy
,
M. Grözinger
4   Klinik für Psychiatrie, Psychotherapie und Psychosomatik des Universitätsklinikums, Aachen, Germany
› Author Affiliations
Further Information

Publication History

received 21 October 2012
revised 03 April 2013

accepted 24 April 2013

Publication Date:
04 June 2013 (online)

Also available at
   Permissions and Reprints

Abstract

Sexual dysfunction is a potential side effect of antipsychotic drugs: this article presents a critical review of the current literature. Although many studies have been published on the subject, only some used a validated sexual function rating scale and most lacked either a baseline or placebo control or both. In addition, many of the studies on sexual dysfunction associated with antipsychotic medication are limited by other methodological flaws. However, there is consistent evidence to suggest that a large number of antipsychotic drugs adversely affect one or more of the 3 phases of sexual response (desire, arousal and orgasm). Among the antipsychotics, the so called “prolactin-raising” are probably most associated with sexual dysfunction, even if further studies to confirm this are needed: the reviewed literature shows no consistent evidence that any one antipsychotic drug has a significantly superior side effect profile over another and current information on this topic is often based on methodologically weak research. Clinicians must be aware of drug-induced sexual dysfunction, since its presence can have important consequences for clinical management and compliance.

Key words

antipsychotic drugs - sexual dysfunction - sexual side effects - treatment-emergent sexual dysfunction
 

  • References

  • 1 Berner MM, Hagen M, Kriston L et al. Management of sexual dysfunction due to antipsychotics drug therapy. Cochrane Database of Systematic Reviews 2007; 1-24 DOI: 10.1002/14651858.CD003546.pub2.
    PubMedGoogle Scholar
  • 2 Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002; 36: 143-164
    PubMedGoogle Scholar
  • 3 Knegtering H, Van den Moolen AEGM, Castelein S et al. What are the effects of antipsychotics on sexual dysfunction and endocrine functioning?. Psychoneuroendocrinology 2003; 28: 109-123
    CrossrefPubMedGoogle Scholar
  • 4 Labbate LA. Psychotropics and sexual dysfunction: the evidence and treatments. Adv Psychosom Med 2008; 29: 107-130
    PubMedGoogle Scholar
  • 5 Gitlin M. Sexual dysfunction with psychotropic drugs. Expert Opin Pharmacother 2003; 4: 2259-2269
    CrossrefPubMedGoogle Scholar
  • 6 Tardieu S, Micallef J, Bonierbale M et al. Sexual behaviour in schizophrenic patients: the impact of antipsychotics. Encephale 2006; 32: 697-704
    CrossrefPubMedGoogle Scholar
  • 7 Akhtar S, Thompson Jr JA. Schizophrenia and sexuality: a review and a report of twelve unusual cases, part I. J Clin Psychiatry 1980; 41: 134-142
    PubMedGoogle Scholar
  • 8 Akhtar S, Thompson Jr JA. Schizophrenia and sexuality: a review and a report of twelve unusual cases, part II. J Clin Psychiatry 1980; 41: 166-174
    PubMedGoogle Scholar
  • 9 Peuskens J, Sienaert P, De Hert M. Sexual dysfunction: the unspoken side effect of antipsychotics. Eur Psychiatry 1998; 13: 23s-30s
    CrossrefPubMedGoogle Scholar
  • 10 Dervaux A, El Omari F. Sexual dysfunction in schizophrenics patients, the role of antipsychotics. Presse Med 2005; 34: 529-532
    CrossrefPubMedGoogle Scholar
  • 11 Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011; 26: 130-140
    CrossrefPubMedGoogle Scholar
  • 12 Serretti A, Chiesa A. Sexual side effects of pharmacological treatment of psychiatric diseases. Clin Pharmacol Ther 2011; 89: 142-147
    CrossrefPubMedGoogle Scholar
  • 13 Brugnoli R, Novick D, Belger M et al. Effectiveness of antipsychotic treatment for schizophrenia: Italian results of the pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study after 12 months. Giornale Italiano di Psicopatologia 2006; 12: 283-292
    PubMedGoogle Scholar
  • 14 Dossenbach M, Erol A, el Mahfoud Kessaci M et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. IC-SOHO Study Group. J Clin Psychiatry 2004; 65: 312-321
    CrossrefPubMedGoogle Scholar
  • 15 Eberhard J, Lindström E, Holstad M et al. Prolactin level durin 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 2007; 115: 268-276
    CrossrefPubMedGoogle Scholar
  • 16 Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study. Implications for the treatment of schizophrenia. CNS Drugs 2006; 20: 293-301
    CrossrefPubMedGoogle Scholar
  • 17 Mullen B, Brar JS, Vagnucci AH et al. Frequency of sexual dysfunction in patients with schizophrenia on haloperidol, clozapine, or risperidone. Schizophr Res 2001; 48: 155-158
    CrossrefPubMedGoogle Scholar
  • 18 Treuer T, Anders M, Bitter I et al. Effectiveness and tolerability of schizophrenia treatment in central and eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO). Int J Psychiatr Clin Pract 2006; 10: 78-90
    CrossrefPubMedGoogle Scholar
  • 19 Assalian P, Fraser R, Tempier R et al. Sexuality and quality of life of patients with schizophrenia. Int J Psychiatr Clin Pract 2000; 4: 29-33
    CrossrefPubMedGoogle Scholar
  • 20 Compton MT, Miller AH. Sexual side effects associated with conventional and atypical antipsychotics. Psychopharmacol Bull 2001; 35: 89-108
    PubMedGoogle Scholar
  • 21 Higgins A, Barker P, Begley CM. Neuroleptic medication and sexuality: the forgotten aspect of education and care. J Psychiatr Ment Health Nurs 2005; 12: 439-446
    CrossrefPubMedGoogle Scholar
  • 22 Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophr Bull 2004; 30: 767-779
    CrossrefPubMedGoogle Scholar
  • 23 Murthy S, Wylie K. Sexual problems in patients on antipsychotic medication. Sex Relation Ther 2007; 22: 97-107
    CrossrefPubMedGoogle Scholar
  • 24 Lukoff D, Gioia-Hasick D, Sullivan G et al. Sex education and rehabilitation with schizophrenic male outpatients. Schizophr Bull 1986; 12: 669-677
    CrossrefPubMedGoogle Scholar
  • 25 Cutler AJ. Sexual dysfunction and antipsychotics treatment. Psychoneuroendocrinology 2003; 28: 69-82
    PubMedGoogle Scholar
  • 26 Dossenbach M, Hodge A, Anders M et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol 2005; 8: 195-201
    CrossrefPubMedGoogle Scholar
  • 27 Fortier P, Mottard JP, Trudel G et al. Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults. Schizophr Bull 2003; 29: 559-572
    CrossrefPubMedGoogle Scholar
  • 28 Nnaji RN, Friedman T. Sexual dysfunction and schizophrenia: psychiatrist’ attitudes and training needs. Psychiatric Bull 2008; 32: 208-210
    CrossrefPubMedGoogle Scholar
  • 29 Apantaku-Olajide T, Gibbons P, Higgins A. Drug-induced sexual dysfunction and mental health patients’ attitude to psychotropic medications. Sex Relation Ther 2011; 26: 145-155
    CrossrefPubMedGoogle Scholar
  • 30 Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008; 23: 201-209
    CrossrefPubMedGoogle Scholar
  • 31 Dossenbach M, Dyachkova Y, Pirildar S et al. Effects of atypical and typical antypsichotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatients Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006; 21: 251-258
    PubMedGoogle Scholar
  • 32 Hamer S, Haddad PM. Adverse effects of antipsychotics as outcome measures. Br J Psychiatry 2007; 191: s64-s70
    CrossrefPubMedGoogle Scholar
  • 33 Kelly DL, Conley RR. Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophr Res 2003; 63: 195-196
    CrossrefPubMedGoogle Scholar
  • 34 Khawaja MY. Sexual dysfunction in male patients taking antipsychotics. J Ayub Med Coll Abbottabad 2005; 17: 73-75
    PubMedGoogle Scholar
  • 35 Lambert M, Conus P, Eide P et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004; 19: 415-422
    CrossrefPubMedGoogle Scholar
  • 36 Rosenberg KP, Bleiberg KL, Koscis J et al. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003; 29: 289-296
    CrossrefPubMedGoogle Scholar
  • 37 Smith SM, O’Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002; 181: 49-55
    CrossrefPubMedGoogle Scholar
  • 38 Macdonald S, Halliday J, MacEwan T et al. Nithsdale schizophrenia surveys 24: sexual dysfunction. Case-control study. Br J Psychiatry 2003; 182: 50-56
    CrossrefPubMedGoogle Scholar
  • 39 Fan X, Henderson DC, Chiang E et al. Sexual functioning, psychopatology and quality of life in patients with schizophrenia. Schizophr Res 2007; 94: 119-127
    CrossrefPubMedGoogle Scholar
  • 40 Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982; 170: 453-467
    PubMedGoogle Scholar
  • 41 Fujii A, Yasui-Furukori N, Sugawara N et al. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 288-293
    CrossrefPubMedGoogle Scholar
  • 42 Knegtering H, Blijd C, Boks MPM. Sexual dysfunction and prolactin levels in patients using classical antipsychotics, risperidone or olanzapine. Schizophr Res 1999; 36: 355-356
    PubMedGoogle Scholar
  • 43 Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911-936
    CrossrefPubMedGoogle Scholar
  • 44 Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia. Mechanisms, clinical features and management. Drugs 2004; 64: 2291-2314
    CrossrefPubMedGoogle Scholar
  • 45 Knegtering H. Antipsychotic treatment and sexual functioning, the role of prolactin. University of Groningen; The Netherlands: 2003. Available on line at http://irs.ub.rug.nl/ppn/254939104
    Google Scholar
  • 46 Knegtering H, Bruggeman R. What are the effects of antipsychotics on sexual functioning?. Prim Psychiatry 2007; 14: 51-56
    PubMedGoogle Scholar
  • 47 Westheide J, Cohen S, Bender S et al. Sexual dysfunction in psychiatric inpatients the role of antipsychotic medication. Pharmacopsychiatry 2007; 40: 140-145
    Google Scholar
  • 48 Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. (third edition). New York: Cambridge University Press; 2008
    Google Scholar
  • 49 Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13: 27-35
    CrossrefPubMedGoogle Scholar
  • 50 Andersohn F, Schmedt N, Weinmann S et al. Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol 2010; 30: 68-71
    CrossrefPubMedGoogle Scholar
  • 51 Bhuvaneswar CG, Baldessarini RJ, Harsh VL et al. Adverse endocrine and metabolic effects of psychotropic drugs. CNS Drugs 2009; 23: 1003-1021
    CrossrefPubMedGoogle Scholar
  • 52 Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Exp Opin Pharm 2002; 3: 1381-1391
    PubMedGoogle Scholar
  • 53 Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics. A review. Hum Psychopharmacol Clin Exp 2010; 25: 281-297
    CrossrefPubMedGoogle Scholar
  • 54 Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63: 56-62
    PubMedGoogle Scholar
  • 55 Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-690
    CrossrefPubMedGoogle Scholar
  • 56 Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci 2005; 42: 51-60
    PubMedGoogle Scholar
  • 57 Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004; 20: 189-197
    CrossrefPubMedGoogle Scholar
  • 58 Liu-Seifert H, Kinon BJ, Tennant CJ et al. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat 2009; 5: 47-54
    PubMedGoogle Scholar
  • 59 Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 2008; 18: S 108-S 114
    CrossrefPubMedGoogle Scholar
  • 60 Rettenbacher MA, Hofer A, Ebenbichler C et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol 2010; 30: 711-715
    CrossrefPubMedGoogle Scholar
  • 61 Smith SM. The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol 2008; 22: 63-69
    CrossrefPubMedGoogle Scholar
  • 62 Howes OD, Wheeler MJ, Pilowsky LS et al. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry 2007; 68: 361-367
    CrossrefPubMedGoogle Scholar
  • 63 Hummer M, Kemmler G, Kurz M et al. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 1999; 156: 631-633
    PubMedGoogle Scholar
  • 64 Kleinberg DL, Davis JM, de Coster R et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychoharmacol 1999; 19: 57-61
    PubMedGoogle Scholar
  • 65 Konarzewska B, Wolczyński S, Szulc A et al. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009; 34: 129-139
    CrossrefPubMedGoogle Scholar
  • 66 Johnsen E, Kroken R, Loberg EM et al. Sexual dysfunction and hyperprolactinemia in male psychotic inpatients: a cross-sectional study. Adv Urol 2011; article ID 686924
    PubMedGoogle Scholar
  • 67 Yasui-Furukori N, Fujii A, Sugawara N et al. No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Hum Psychopharmacol 2012; 27: 82-89
    CrossrefPubMedGoogle Scholar
  • 68 Knegtering H, Van den Bosch R, Castelein S et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin?. Psychoneuroendocrinology 2008; 33: 711-717
    CrossrefPubMedGoogle Scholar
  • 69 Westheide J, Cvetanovska G, Albrecht C et al. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med 2008; 5: 2816-2826
    CrossrefPubMedGoogle Scholar
  • 70 Istikoglou C, Vlissides D, Michelidakis K et al. Quality of life: sexual dysfunction in young people with schizophrenia treated with ziprasidone. Eur Neuropsychopharm 2009; 19: S511
    PubMedGoogle Scholar
  • 71 Van Bruggen M, Van Amelsvoort T, Wouters L et al. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology 2009; 34: 989-995
    CrossrefPubMedGoogle Scholar
  • 72 Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999; 35: S75-S86
    CrossrefPubMedGoogle Scholar
  • 73 Wieck A, Haddad M. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003; 182: 199-204
    CrossrefPubMedGoogle Scholar
  • 74 Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-1349
    CrossrefPubMedGoogle Scholar
  • 75 Smith S, Wheeler MJ, Murray R et al. The effects of antipsychotic-induced hyperprolactinaemia on the hypotalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002; 22: 109-114
    CrossrefPubMedGoogle Scholar
  • 76 American Psychiatric Association. Practise guidelines for the treatment of patients with schizophrenia. Second edition. April 2004. Available on line at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_6.aspx
    PubMedGoogle Scholar
  • 77 Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158: 765-774
    CrossrefPubMedGoogle Scholar
  • 78 Chrzanowski WK, Marcus RN, Torbeyns A et al. Effectiveness of long-term aripripazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006; 189: 259-266
    CrossrefPubMedGoogle Scholar
  • 79 Volavka J, Czobor P, Cooper TB et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004; 65: 57-61
    CrossrefPubMedGoogle Scholar
  • 80 Potkin SG. Asenapine: a critical overview. J Clin Psychiatry 2011; 72: 14-18
    CrossrefPubMedGoogle Scholar
  • 81 Weber J, McCormack PL. Asenapine. CNS Drugs 2009; 23: 781-792
    CrossrefPubMedGoogle Scholar
  • 82 Citrome L. Iloperidone: a critical overview. J Clin Psychiatry 2011; 72: 19-23
    CrossrefPubMedGoogle Scholar
  • 83 Kane L. Lurasidone: a critical overview. J Clin Psychiatry 2011; 72: 24-28
    CrossrefPubMedGoogle Scholar
  • 84 Montgomery J, Winterbottom E, Jessani M et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atipical antipsychotic treatment. J Clin Psychiatry 2004; 65: 1492-1498
    PubMedGoogle Scholar
  • 85 Baldwin D, Mayers A. Sexual side-effects of antidepressant and antipsychotic drug. Adv Psychiatric Treatment 2003; 9: 202-210
    PubMedGoogle Scholar
  • 86 Aizenberg D, Zemishlany Z, Dorfman-Etrog P et al. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995; 56: 137-141
    PubMedGoogle Scholar
  • 87 Boora K, Chiappone K, Dubovsky S et al. Ziprasidone-induced spontaneous orgasm. J Psychopharmacol 2010; 24: 947-948
    CrossrefPubMedGoogle Scholar
  • 88 Freeman SA. Iloperidone-induced retrograde ejaculation. Int Clin Psychopharmacol 2013; [Epub ahead of print] DOI: 10.1097/YIC.0b013e32835e9112.
    PubMedGoogle Scholar
  • 89 Orazzo C, Bortolotti F, Monteleone P. Gli psicofarmaci e la funzionalità sessuale nella pratica clinica. Available on line at http://www.psychiatryonline.it/ital/riviste/quaderni/orazzo.htm (latest access on 18 february 2013)
    PubMedGoogle Scholar
  • 90 Kotin J, Wilbert DE, Verburg D et al. Thioridazine and sexual dysfunction. Am J Psichiatry 1976; 133: 82-85
    PubMedGoogle Scholar
  • 91 Degen K. Sexual dysfunction in women using major tranquilizers. Psychosomatics 1982; 23: 959-961
    CrossrefPubMedGoogle Scholar
  • 92 Compton MT, Miller AH. Priapism associated with conventional and atypical antipsychotic medications: a review. J Clin Psychiatry 2001; 62: 362-366
    CrossrefPubMedGoogle Scholar
  • 93 Mago R, Anolik R, Johnson RA et al. Recurrent priapism associated with use of aripiprazole. J Clin Psychiatry 2006; 67: 1471-1472
    CrossrefPubMedGoogle Scholar
  • 94 Penaskovic KM, Haq F, Raza S. Priapism during treatment with Olanzapine, Quetiapine, and Risperidone in a patient with schizophrenia: a case report. Prim Care Companion J Clin Psychiatry 2010; 12 PCC.09l00939 DOI: 10.4088/PCC.09l00939yel.
    PubMedGoogle Scholar
  • 95 Torun F, Yilmaz E, Gumus E. Priapism due to a single dose of quetiapine. Turk Psikiyatri Derg 2011; 22: 195-199
    PubMedGoogle Scholar
  • 96 Kaufman KR, Stern L, Mohebati A et al. Ziprasidone-induced priapism requiring surgical treatment. Eur Psychiatry 2006; 21: 48-50
    CrossrefPubMedGoogle Scholar
  • 97 Reeves RR, Kimble R. Prolonged erections associated with ziprasidone treatment: a case report. J Clin Psychiatry 2003; 64: 97-98
    CrossrefPubMedGoogle Scholar
  • 98 Malik P. Sexual dysfunction in schizophrenia. Curr Opin Psychiatry 2007; 20: 138-142
    CrossrefPubMedGoogle Scholar
  • 99 Malik P. Sexual dysfunction in schizophrenia. Focus 2008; 6: 234-238
    PubMedGoogle Scholar
  • 100 Rico-Villademoros F, Calandre EP. Antipsychotic-induced sexual dysfunction and the strength of the evidence. J Clin Psychiatry 2005; 66: 1074-1075
    CrossrefPubMedGoogle Scholar
  • 101 Kelly DL, Conley RR. A randomized double-blind 12-week study of quietapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006; 31: 340-346
    CrossrefPubMedGoogle Scholar
  • 102 Knegtering H, Boks M, Blijd C et al. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther 2006; 32: 315-326
    CrossrefPubMedGoogle Scholar
  • 103 Bobes J, Garcia-Portilla MP, Rejas J et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE Study. J Sex Marital Ther 2003; 29: 125-147
    CrossrefPubMedGoogle Scholar
  • 104 Uçok A, Incensu C, Aker T et al. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry 2007; 22: 328-333
    CrossrefPubMedGoogle Scholar
  • 105 Nakonezny PA, Byerly MJ, Rush AJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther 2007; 33: 203-216
    CrossrefPubMedGoogle Scholar
  • 106 Byerly MJ, Nakonezny PA, Bettcher BM et al. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res 2006; 86: 244-250
    CrossrefPubMedGoogle Scholar
  • 107 Nagaraj AK, Pai NB, Rao S. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. Indian J Psychiatry 2009; 51: 265-271
    CrossrefPubMedGoogle Scholar
  • 108 Byerly MJ, Nakonezny PA, Rush AJ. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial. Psychiatry Res 2008; 159: 115-120
    CrossrefPubMedGoogle Scholar
  • 109 Strous RD, Kupchik M, Roitman S et al. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Hum Psychopharmacol 2006; 21: 235-243
    CrossrefPubMedGoogle Scholar
  • 110 Bitter I, Basson BR, Dossenbach MR. Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients. Int Clin Psychopharmacol 2005; 20: 19-21
    CrossrefPubMedGoogle Scholar
  • 111 Mahmoud A, Hayhurst KP, Drake RJ et al. Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial. Schizophrenia Research and Treatment 2011; Article ID 596898 DOI: 10.1155/2011/596898.
    PubMedGoogle Scholar
  • 112 Montejo AL, Majadas S, Rico-Villademoros F et al. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med 2010; 7: 3404-3413
    CrossrefPubMedGoogle Scholar
  • 113 Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol 2012; 26: 42-51
    CrossrefPubMedGoogle Scholar
  • 114 Paparrigopoulos T, Liappas J, Tzavellas E. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychoparmacol Biol Psychiatry 2007; 31: 92-96
    PubMedGoogle Scholar
  • 115 Raj R, Sidhu BS. Hyperprolactinaemia with amisulpride. Indian J Psychiatry 2008; 5: 54-56
    PubMedGoogle Scholar
  • 116 Kerwin R, Millet B, Herman E et al. A multicentre, randomized, naturalistic, open-label study between aripripazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripripazole: (STAR) study. Eur Psychiatry 2007; 22: 433-443
    CrossrefPubMedGoogle Scholar
  • 117 Montejo AL, Campos MC, Fombellida C et al. Prospective, multicenter, open-label, observational study of sexual function in patients beginning aripiprazole treatment. Eur Psychiatry 2008; 23: S133-S134
    PubMedGoogle Scholar
  • 118 Mir A, Shivakumar K, Williamson RJ et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008; 22: 244-253
    CrossrefPubMedGoogle Scholar
  • 119 Casey DE, Carson WH, Saha AR et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacol 2003; 166: 391-399
    PubMedGoogle Scholar
  • 120 Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 714-717
    CrossrefPubMedGoogle Scholar
  • 121 Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123-136
    CrossrefPubMedGoogle Scholar
  • 122 Aizenberg D, Modai I, Landa A et al. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapina. J Clin Psychiatry 2001; 62: 541-544
    CrossrefPubMedGoogle Scholar
  • 123 Deschenes S, Courtois F, Lafond J. Potential side effects of clozapine on the sexual function of schizophrenic man. J Sex Educ Ther 2001; 26: 334-339
    PubMedGoogle Scholar
  • 124 Breier AF, Malhotra AK, Su T-P et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, Parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999; 156: 294-298
    PubMedGoogle Scholar
  • 125 Yusufi B, Mukherjee S, Flanagan R et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 2007; 22: 238-243
    CrossrefPubMedGoogle Scholar
  • 126 Grootens KP, Van Veelen NM, Peuskens J et al. Ziprasidone versus olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull 2011; 37: 352-361
    CrossrefPubMedGoogle Scholar
  • 127 Costa AM, de Lima MS, Faria M et al. A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. J Psychopharmacol 2007; 21: 165-170
    CrossrefPubMedGoogle Scholar
  • 128 Kinon BJ, Ahl J, Liu-Seifert H et al. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006; 31: 577-588
    CrossrefPubMedGoogle Scholar
  • 129 Knegtering R, Castelein S, Bous H et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004; 24: 56-61
    CrossrefPubMedGoogle Scholar
  • 130 Atmaca M, Kuloglu M, Tezcan E. A new atypical antipsychotic: quetiapine-induced sexual dysfunctions. Int J Imp Res 2005; 17: 201-203
    CrossrefPubMedGoogle Scholar
  • 131 Byerly MJ, Lescouflair E, Weber MT et al. An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. J Sex Marital Ther 2004; 30: 325-332
    CrossrefPubMedGoogle Scholar
  • 132 Menon A, Williams RH, Watson S. Increased libido associated with quietiapine. J Psychopharmacol 2006; 20: 125-127
    PubMedGoogle Scholar
  • 133 Montejo González AL, Rico-Villademoros F, Tafalla M et al. A 6-month prospective observational study on the effects of quetiapina on sexual functioning. J Clin Psychopharmacol 2005; 25: 533-538
    CrossrefPubMedGoogle Scholar
  • 134 Wirshing DA, Pierre JM, Marder SR et al. Sexual side effects of novel antipsychotic medications. Schizophr Res 2002; 56: 25-30
    CrossrefPubMedGoogle Scholar
  • 135 Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multicentre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-726
    CrossrefPubMedGoogle Scholar
  • 136 David SR, Taylor CC, Kinon BJ et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22: 1085-1096
    CrossrefPubMedGoogle Scholar
  • 137 Berwaerts J, Cleton A, Rossenu S et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol 2010; 24: 1011-1018
    CrossrefPubMedGoogle Scholar
  • 138 Montejo AL, Rico-Villademoros F. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study. J Clin Psychopharmacol 2008; 28: 568-570
    CrossrefPubMedGoogle Scholar
  • 139 Rossi A, Vita A, Tiradritti P et al. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol 2008; 23: 216-222
    CrossrefPubMedGoogle Scholar
  • 140 Duncan D, Taylor D. Treatment of psychotropic-induced hyperprolactinaemia. Psychiatric Bull 1995; 19: 755-757
    CrossrefPubMedGoogle Scholar
  • 141 Gopalakrishnan R, Jacob KS, Kuruvilla A et al. Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry 2006; 163: 494-499
    CrossrefPubMedGoogle Scholar
  • 142 Kodesh A, Weizman A, Aizenberg D et al. Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study. Clin Neuropharmacol 2003; 26: 193-195
    CrossrefPubMedGoogle Scholar
  • 143 Costa AM, Lima MS, Mari Jde J. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J 2006; 124: 291-297
    PubMedGoogle Scholar
  • 144 Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 2011; 45: 830-837
    CrossrefPubMedGoogle Scholar
  • 145 Nunes LV, Moreira HC, Razzouk D et al. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther 2012; 38: 281-301
    CrossrefPubMedGoogle Scholar
  • 146 Schmidt HM, Hagen M, Kriston L et al. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev 2012; DOI: 10.1002/14651858.CD003546.pub3.
    PubMedGoogle Scholar